Tumor microenvironment modifications induced by soluble VEGF receptor expression in a rat liver metastasis model

Cancer Letters

Volumn 298, Issue 2, 2010, Pages 264-272

  Bertin, Samuel ^a   Mohsen Kanson, Tala ^a   Baqué, Patrick ^a,b   Gavelli, Adolfo ^a,c   Momier, David ^d   Anjuere, Fabienne ^a   Carle, Georges F ^d   Pierrefite Carle, Valérie ^a,d  

^a INSERM   (France)

^b University Hospital of Nice University of Nice Sophia Antipolis   (France)

^c CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Colon carcinoma; Liver metastasis; Myeloid cells; VEGF

Indexed keywords

VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; IMMUNOHISTOLOGY; IN VIVO STUDY; LIVER METASTASIS; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; RAT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINES; COLONIC NEOPLASMS; CULTURE MEDIA, CONDITIONED; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MYELOID CELLS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED STRAINS; TRANSFECTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

RATTUS;

EID: 77957961198     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.017     Document Type: Article

References (38)

1. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
2. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991.
3. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187:1579-1586.
4. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 1996, 2:1096-1103.
5. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
6. Kusmartsev S., Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 2005, 174:4880-4891.
7. Melani C., Chiodoni C., Forni G., Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145.
8. Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 2004, 172:989-999.
9. Sinha P., Clements V.K., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 2005, 174:636-645.
10. Ochoa A.C., Zea A.H., Hernandez C., Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007, 13:721s-726s.
11. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
12. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor associated immunodeficiency. Immunol. Res. 2001, 23:263-272.
13. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Rev. Cancer 2008, 8:592-603.
14. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
15. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotech. 2007, 25:911-920.
16. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
17. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 1993, 90:10705-10709.
18. Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 1996, 226:324-328.
19. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. J. Biol. Chem. 1994, 269:25646-25654.
20. Yamaguchi T., Bando H., Mori T., Takahashi K., Matsumoto H., Yasutome M., Weich H., Toi M. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci. 2007, 98:405-410.
21. Martin F., Caignard A., Jeannin J.F., Leclerc A., Martin M. Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int. J. Cancer 1983, 32:623-627.
22. Auerbach R., Morissey L.W., Sidky Y.A. Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation. Cancer Res. 1978, 38:1739-1744.
23. Bertin S., Neves S., Gavelli A., Baqué P., Brossette N., Simões S., Pedroso M.C., de Lima V., Pierrefite-Carle V. Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model. Cancer Gene Ther. 2007, 14:858-866.
24. Yoshimura I., Mizuguchi Y., Miyajima A., Asano T., Tadakuma T., Hayakawa M. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J. Urol. 2004, 171:2467-2470.
25. Schmidt K., Hoffend J., Altmann A., Strauss L.G., Dimitrakopoulou-Strauss A., Engelhardt B., Koczan D., Peter J., Vorwald S., Eskerski H., Eisenhut M., Metz J., Kinscherf R., Haberkorn U. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin. Cancer Res. 2005, 11:2132-2140.
26. Kommareddy S., Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 2007, 14:488-498.
27. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
28. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
29. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
30. Li B., Vincent A., Cates J., Brantley-Sieders D.M., Polk D.B., Young P.P. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009, 69:338-348.
31. Sanchez-Elsner T., Botella L.M., Velasco B., Corbi A., Attisano L., Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 2001, 276:38527-38535.
32. Bar D., Apte R.N., Voronov E., Dinarello C.A., Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 2004, 18:161-163.
33. Hedrick J.A., Zlotnik A. Lymphotactin. Clin. Immunol. Immunopathol. 1998, 87:218-222.
34. Yoshida T., Imai T., Takagi S., Nishimura M., Ishikawa I., Yaoi T., Yoshie O. Structure and expression of two highly related genes encoding SCM-1/human lymphotactin. FEBS Lett. 1996, 395:82-88.
35. Broxmeyer H.E., Kim C.H., Cooper S.H., Hangoc G., Hromas R., Pelus L.M. Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann. NY Acad. Sci. 1999, 872:142-162.
36. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
37. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
38. Makarenkova V.P., Bansal V., Matta B.M., Perez L.A., Ochoa J.B. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 2006, 176:2085-2094.